{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:35:52Z","timestamp":1790516152003,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T00:00:00Z","timestamp":1409011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s10238-014-0304-7","type":"journal-article","created":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T03:48:36Z","timestamp":1408938516000},"page":"245-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of prostaglandin I2 analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage"],"prefix":"10.1007","volume":"15","author":[{"given":"Ming-Kai","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Chao","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Fu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Sheng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yii","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsing","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,26]]},"reference":[{"key":"304_CR1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199802123380706","volume":"338","author":"AD Luster","year":"1998","unstructured":"Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436\u201345.","journal-title":"N Engl J Med"},{"key":"304_CR2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/heart.83.3.361","volume":"83","author":"MJ Davies","year":"2000","unstructured":"Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000;83:361\u20136.","journal-title":"Heart"},{"key":"304_CR3","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1582-4934.2008.00261.x","volume":"12","author":"L Zhong","year":"2008","unstructured":"Zhong L, Chen WQ, Ji XP, Zhang M, Zhao YX, Yao GH, et al. Dominant-negative mutation of monocyte chemoattractant protein-1 prevents vulnerable plaques from rupture in rabbits independent of serum lipid levels. J Cell Mol Med. 2008;12:2362\u201371.","journal-title":"J Cell Mol Med"},{"key":"304_CR4","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1161\/01.CIR.0000018603.67989.71","volume":"105","author":"E Mori","year":"2002","unstructured":"Mori E, Komori K, Yamaoka T, Tanii M, Kataoka C, Takeshita A, et al. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation. 2002;105:2905\u201310.","journal-title":"Circulation"},{"key":"304_CR5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1253\/circj.CJ-11-1457","volume":"76","author":"J Li","year":"2012","unstructured":"Li J, Guo Y, Luan X, Qi T, Li D, Chen Y, Ji X, Zhang Y, Chen W. Independent roles of monocyte chemoattractant protein-1, regulated on activation, normal T-cell expressed and secreted and fractalkine in the vulnerability of coronary atherosclerotic plaques. Circ J. 2012;76:2167\u201373.","journal-title":"Circ J"},{"key":"304_CR6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clim.2009.04.008","volume":"134","author":"Z Kaya","year":"2010","unstructured":"Kaya Z, Katus HA, Rose NR. Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure. Clin Immunol. 2010;134:80\u20138.","journal-title":"Clin Immunol"},{"key":"304_CR7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/CS20080581","volume":"117","author":"J Niu","year":"2009","unstructured":"Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond). 2009;117:95\u2013109.","journal-title":"Clin Sci (Lond)"},{"key":"304_CR8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1096\/fj.03-0645rev","volume":"18","author":"TD Warner","year":"2004","unstructured":"Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790\u2013804.","journal-title":"FASEB J"},{"key":"304_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.plefa.2003.04.002","volume":"70","author":"RJ Helliwell","year":"2004","unstructured":"Helliwell RJ, Adams LF, Mitchell MD. Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids. 2004;70:101\u201313.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"304_CR10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ni1188","volume":"6","author":"T Kunikata","year":"2005","unstructured":"Kunikata T, Yamane H, Segi E, et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol. 2005;6:524\u201331.","journal-title":"Nat Immunol"},{"key":"304_CR11","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.178.3.1628","volume":"178","author":"DM Aronoff","year":"2007","unstructured":"Aronoff DM, Peres CM, Serezani CH, Ballinger MN, Carstens JK, Coleman N, Moore BB, Peebles RS, Faccioli LH, Peters-Golden M. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol. 2007;178:1628\u201334.","journal-title":"J Immunol"},{"key":"304_CR12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1172\/JCI28949","volume":"117","author":"M Idzko","year":"2007","unstructured":"Idzko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, Lambrecht BN. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest. 2007;117:464\u201372.","journal-title":"J Clin Invest"},{"key":"304_CR13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/09031936.00070008","volume":"33","author":"CH Hung","year":"2009","unstructured":"Hung CH, Chu YT, Suen JL, Lee MS, Chang HW, Lo YC, Jong YJ. Regulation of cytokine expression in human plasmacytoid dendritic cells by prostaglandin I2 analogues. Eur Respir J. 2009;33:405\u201310.","journal-title":"Eur Respir J"},{"key":"304_CR14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1536\/ihj.53.64","volume":"53","author":"J Suzuki","year":"2012","unstructured":"Suzuki J, Ogawa M, Sakai Y, Hirata Y, Isobe M, Nagai R. A prostacycline analog prevents chronic myocardial remodeling in murine cardiac allografts. Int Heart J. 2012;53:64\u20137.","journal-title":"Int Heart J"},{"key":"304_CR15","doi-asserted-by":"crossref","first-page":"e8668","DOI":"10.1371\/journal.pone.0008668","volume":"5","author":"M Daigneault","year":"2010","unstructured":"Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE. 2010;5:e8668.","journal-title":"PLoS ONE"},{"key":"304_CR16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00109-010-0694-2","volume":"89","author":"CH Kuo","year":"2011","unstructured":"Kuo CH, Ko YC, Yang SN, Chu YT, Wang WL, Huang SK, Chen HN, Wei WJ, Jong YJ, Hung CH. Effects of PGI2 analogues on Th1- and Th2-related chemokines in monocytes via epigenetic regulation. J Mol Med. 2011;89:29\u201341.","journal-title":"J Mol Med"},{"key":"304_CR17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4049\/jimmunol.178.2.702","volume":"178","author":"W Zhou","year":"2007","unstructured":"Zhou W, Hashimoto K, Goleniewska K, O\u2019Neal JF, Ji S, Blackwell TS, Fitzgerald GA, Egan KM, Geraci MW, Peebles RS Jr. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol. 2007;178:702\u201310.","journal-title":"J Immunol"},{"key":"304_CR18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1096\/fj.03-0645rev","volume":"18","author":"TD Warner","year":"2004","unstructured":"Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790\u2013804.","journal-title":"FASEB J"},{"key":"304_CR19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1172\/JCI28949","volume":"117","author":"M Idzko","year":"2007","unstructured":"Idzko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, Lambrecht BN. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest. 2007;117:464\u201372.","journal-title":"J Clin Invest"},{"key":"304_CR20","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","volume":"342","author":"MM Hoeper","year":"2000","unstructured":"Hoeper MM, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866\u201370.","journal-title":"N Engl J Med"},{"key":"304_CR21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/157489009789152230","volume":"4","author":"MK Ohman","year":"2009","unstructured":"Ohman MK, Eitzman DT. Targeting MCP-1 to reduce vascular complications of obesity. Recent Pat Cardiovasc Drug Discov. 2009;4:164\u201376.","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"304_CR22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/fca.09.4","volume":"5","author":"IT Daissormont","year":"2009","unstructured":"Daissormont IT, Kraaijeveld AO, Biessen EA. Chemokines as therapeutic targets for atherosclerotic plaque destabilization and rupture. Future Cardiol. 2009;5:273\u201384.","journal-title":"Future Cardiol"},{"key":"304_CR23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199243060-00008","volume":"43","author":"SM Grant","year":"1992","unstructured":"Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs. 1992;43:889\u2013924.","journal-title":"Drugs"},{"key":"304_CR24","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.178.3.1628","volume":"178","author":"DM Aronoff","year":"2007","unstructured":"Aronoff DM, Peres CM, Serezani CH, Ballinger MN, Carstens JK, Coleman N, Moore BB, Peebles RS, Faccioli LH, Peters-Golden M. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog\u2013receptor binding specificities. J Immunol. 2007;178:1628\u201334.","journal-title":"J Immunol"},{"key":"304_CR25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","volume":"79","author":"S Narumiya","year":"1999","unstructured":"Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193\u2013226.","journal-title":"Physiol Rev"},{"key":"304_CR26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1536\/ihj.53.64","volume":"53","author":"J Suzuki","year":"2012","unstructured":"Suzuki J, Ogawa M, Sakai Y, Hirata Y, Isobe M, Nagai R. A prostacycline analog prevents chronic myocardial remodeling in murine cardiac allografts. Int Heart J. 2012;53:64\u20137.","journal-title":"Int Heart J"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-014-0304-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-014-0304-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-014-0304-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T03:57:39Z","timestamp":1565755059000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-014-0304-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,26]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1007\/s10238-014-0304-7","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,26]]}}}